News

Animoca Brands and AlphaTON Capital announce equity and token investments; AlphaTON intends to acquire GAMEE

  • Singapore, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Animoca Brands, the company driving digital property rights to help establish the open metaverse and its associated network effects, and AlphaTON Capital Corp. (Nasdaq: ATON), a specialized digital asset treasury company focused on building a strategic TON reserve and public markets access to the high-growth Telegram ecosystem of more than a billion monthly active users, today announced they have entered into a non-binding letter of intent (“LOI”) proposing equity and token investments including the potential acquisition by AlphaTON Capital of a controlling interest in GAMEE, a wholly owned subsidiary of Animoca Brands.
    09/30/2025

AlphaTON Capital Corp Launches TON Digital Asset Treasury Strategy for the Telegram Ecosystem

  • AlphaTON Capital Unlocks Public Market Access to Toncoin (TON) and Telegram's Billion-User Ecosystem Brittany Kaiser, pioneer in data protection, digital assets, and the public equity markets appointed Chief Executive Officer and Board Member Formerly Portage Biotech Inc. (Nasdaq: PRTG), Renamed AlphaTON Capital Corp with new ticker symbol “ATON” effective as of the opening of the market on September 4, 2025 Initial Financing to Acquire ~$100M TON tokens and Start Corporate Treasury; expected to close on or about September 5, 2025 DOVER, Del., Sept. 03, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp. (“AlphaTON Capital” or the “Company”, formerly Portage Biotech Inc.) (Nasdaq: PRTG, ATON), today announced a financing to acquire ~$100 million TON tokens and establish a specialized digital asset treasury company dedicated to building a strategic TON reserve and providing public markets access to Telegram's rapidly expanding ecosystem of more than a billion monthly active users.
    09/03/2025
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

Portage Biotech Inc. Common Stock (ATON) can sell. Click on Rating Page for detail.

The price of Portage Biotech Inc. Common Stock (ATON) is 11.01 and it was updated on 2025-10-08 13:00:18.

Currently Portage Biotech Inc. Common Stock (ATON) is in undervalued.

News
    
News

AlphaTON Capital Corp Launches TON Digital Asset Treasury Strategy for the Telegram Ecosystem

  • DOVER, DE, Sept. 03, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital Unlocks Public Market Access to Toncoin (TON) and Telegram's Billion-User Ecosystem Brittany Kaiser, pioneer in data protection, digital assets, and the public equity markets appointed Chief Executive Officer and Board Member Formerly Portage Biotech Inc. (Nasdaq: PRTG), renamed AlphaTON Capital Corp with new ticker symbol “ATON” effective as of the opening of the market on September 4, 2025 AlphaTON Capital Corp. (“AlphaTON Capital” or the “Company”, formerly Portage Biotech Inc.) (Nasdaq: PRTG, ATON), today announced a financing to acquire ~$100 million TON tokens and establish a specialized digital asset treasury company dedicated to building a strategic TON reserve and providing public markets access to Telegram's rapidly expanding ecosystem of more than a billion monthly active users.
    Wed, Sep. 03, 2025

Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025

  • DOVER, Del., July 25, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands, with a portfolio of novel multi-targeted therapies for use as monotherapy and in combination, today reported its financial results for the fiscal year ended March 31, 2025.
    Fri, Jul. 25, 2025

Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements

  • DOVER, Del., June 25, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands (“Portage”), announced today that on June 24, 2025, the Company received formal notice from The Nasdaq Stock Market LLC that the Company has evidenced compliance with all applicable requirements for continued listing on The Nasdaq Capital Market.
    Wed, Jun. 25, 2025

Portage Biotech and Compedica Stock-for-Stock Exchange

  • DOVER, Del., June 09, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands (“Portage”) announce that on June 5, 2025 Portage and Compedica Holdings Limited, a company formed under the laws of the Isle of Man (“Compedica”) entered a mutual Subscription Agreement (“Subscription Agreement”).
    Mon, Jun. 09, 2025

Portage Biotech Stock Surges As It Prepares For Human Trial

  • Portage Biotech's PORT-7 showed >90% tumor growth inhibition with anti-PD1 combo in a murine mesothelioma model. PORT-7 single-agent activity outperformed anti-PD1 treatment alone; first-in-human trial preparations are underway.
    Mon, Apr. 28, 2025
SEC Filings
SEC Filings
Press Releases
StockPrice Release
More Headlines
News

Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7

  • DOVER, Del., April 28, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company today reports confirmatory preclinical efficacy data for PORT-7 (TT-4), a selective adenosine A2B receptor inhibitor.
  • 04/28/2025

Why Is Portage Biotech Stock Skyrocketing Friday?

  • Portage Biotech Inc.  PRTG on Thursday presented new preclinical data for PORT-7 (TT-4), a selective Adenosine A2B receptor inhibitor, at the 2025 European Lung Cancer Congress.
  • 03/28/2025

Portage Biotech Shares More Than Double After Results of PORT-7 Tumor Treatment Trial

  • Portage Biotech have more than doubled in the after-hours market after the company reported preclinical results for PORT-7 in a murine mesothelioma model.
  • 03/27/2025

Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial

  • Encouraging Safety Profile Supports Progression Toward First Dual-Administration of Selective A2A and A2B Antagonists in Patients Encouraging Safety Profile Supports Progression Toward First Dual-Administration of Selective A2A and A2B Antagonists in Patients
  • 03/12/2025

Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements

  • DOVER, Del., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Portage Biotech, Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, today announced that on February 11, 2025, it received notification from The Nasdaq Stock Market, LLC (“Nasdaq”) that Nasdaq has accepted Portage's compliance plan and has granted the Company the extension to regain compliance with the continued listing standards on The Nasdaq Capital Market (the “Capital Market”) as set forth in Nasdaq Listing Rule 5550(b)(1) whereby the minimum shareholders' equity is at least $2.5 million or meet either of the alternative continued listing standards for the Capital Market, relating to market value of listed securities of at least $35 million or net income from continued operations of at least $500,000 in the most recently completed fiscal year or in two of the last three most recently completed fiscal years.
  • 02/12/2025

Portage Biotech Announces Completion of $2.15 Million Private Financing

  • DOVER, Del., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Portage Biotech, Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, today announced that it has completed a private placement of $2.15 million from two Portage directors.
  • 01/30/2025

Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company

  • WESTPORT, Conn., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Portage Biotech, Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, today announced the re-launch of its wholly-owned subsidiary as an independently managed company focused on developing best-in-class adenosine receptor antagonists.
  • 01/06/2025

Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter

  • No impact at this time on the listing of the Company's Ordinary Shares on Nasdaq Company intends to submit to Nasdaq a compliance plan WESTPORT, Conn., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of novel multi-targeted therapies for use as monotherapy and in combination, announced today that it received written notice (the “Notice”) from The Nasdaq Stock Market, LLC (“Nasdaq”) on December 10, 2024 indicating that the Company was not in compliance with the minimum shareholders' equity requirement for continued listing on The Nasdaq Capital Market (the “Capital Market”) as set forth in Nasdaq Listing Rule 5550(b)(1) (the “Shareholders' Equity Requirement”), because the Company's shareholders' equity of $695,000 as of September 30, 2024, as reported in the Company's Report on Form 6-K containing unaudited condensed consolidated interim financial statements for the three and six months ended September 30, 2024, filed with the United States Securities and Exchange Commission (the “SEC”) on November 26, 2024, was below the required minimum of $2.5 million, and because, as of the date of the Notice (and as of the date of this press release), the Company did not meet either of the alternative continued listing standards for the Capital Market, relating to market value of listed securities of at least $35 million or net income from continuing operations of at least $500,000 in the most recently completed fiscal year or in two of the last three most recently completed fiscal years.
  • 12/12/2024

Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024

  • WESTPORT, Conn., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of novel multi-targeted therapies for use as monotherapy and in combination, today reported its financial results for the fiscal quarter ended September 30, 2024.
  • 11/26/2024

Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives

  • WESTPORT, Conn., April 12, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported that it is expanding its evaluation of strategic alternatives and implementing additional measures to extend its available cash runway.
  • 04/12/2024

Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares

  • Company generated approximately $2.8M of non-dilutive funding to extend cash runway Company generated approximately $2.8M of non-dilutive funding to extend cash runway
  • 03/26/2024

Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update

  • Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update Company focused on adenosine platform clinical development
  • 02/28/2024

Portage Biotech Reports Business and Strategic Update

  • WESTPORT, Conn., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today announced the outcome from the company's comprehensive review of its pipeline in the context of the current capital raising market conditions.
  • 01/04/2024

Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update

  • WESTPORT, Conn., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported financial results for the fiscal quarter ended September 30, 2023.
  • 11/28/2023
Unlock
ATON Ratings Summary
ATON Quant Ranking